This is because the University of Oxford’s COVID-19 vaccine appears to have triggered an immune response in patients both young and old, according to British drugmaker AstraZeneca Plc who is helping to manufacture the vaccine. The company is also claiming that the vaccine produces a lower adverse effect on the elderly who typically have an immune system that is weaker than young people, which is why it is said that the elderly are among those who are considered higher risk when it comes to the coronavirus.
According to a company spokesperson, “It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher. The results further build the body of evidence for the safety and immunogenicity of AZD1222.”
That being said, it should be noted that the vaccine isn’t quite ready for public consumption just yet. It has yet to receive regulatory approval, but according to British Health Secretary Matt Hancock, he believes that it could be ready for a roll out possibly in the first half of 2021.